Réalisées par des traducteurs professionnels, des entreprises, des pages web ou traductions disponibles gratuitement.
in vitro, this metabolite shows minimal inhibition of acetylcholinesterase (<10%).
in vitro kaže ta presnovek zelo majhno stopnjo zaviranja holinesteraze (< 10 %).
rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
rivastigmin deluje tako, da zavira encima, ki razgrajujeta acetilholin: acetilholinesterazo in butirilholinesterazo.
the active substance in rivastigmine 3m health care ltd, rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
zdravilna učinkovina v zdravilu rivastigmin 3m health care ltd, rivastigmin, deluje tako, da zavira encime, ki razgrajujejo acetilholin: acetilholinesterazo in butirilholinesterazo.
as rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours.
ker ima rivastigmin plazemski razpolovni čas okrog 1 ure in traja njegovo zaviranje acetilholinesteraze okrog 9 ur, priporočamo, da v primeru asimptomatičnega prevelikega odmerka bolnik v naslednjih 24 urah ne prejme nadaljnjih odmerkov rivastigmina.
in healthy young men, an oral 3 mg dose decreases acetylcholinesterase (ache) activity in csf by approximately 40 % within the first 1.5 hours after administration.
pri zdravih mladih moških peroralni odmerek 3 mg zmanjša aktivnost acetilholinesteraze (ache) v cerebrospinalni tekočini (csf) za približno 40 % v poldrugi uri po zaužitju.
a meta-analysis of patients with moderate to severe alzheimer’ s disease (mmse total scores < 20) from the six phase iii, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
meta- analiza bolnikov z zmerno do hudo alzheimerjevo boleznijo (skupna ocena kpss ob vključitvi < 20), ki je zajela 6 študij faze iii, kontroliranih s placebom in trajajočih 6 mesecev (vključno s študijami zdravljenja v monoterapiji ter študij bolnikov na stabilnem odmerku inhibitorjev acetilholinesteraze), je pokazala statistično značilen učinek v korist zdravljenja z memantinom na področjih spoznavnih funkcij ter globalnih in funkcionalnih domen.